The Next Fed Chair In Focus… And Mike Wilson’s 2026 Market Playbook 12/4/25

Chatter over President Trump’s next Fed Chair pick is heating up. The latest being heard from D.C., and the front runners likely to take over for Jerome Powell. Plus, just a few weeks left of trading this year, and 2026 could see another double digit gain in the S&P 500. What Morgan Stanley’s Mike Wilson sees in store for stocks, and the sectors he says has the most opportunity.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Could Crude Oil be the new Gold? How the commodities rough year could give way for a high energy trade, and replace the glittering gold rally. Plus Microsoft on the defensive, as the tech giant pushes back against reports its lowering AI sales growth goals. Why one top tech analyst is siding with the company, and what he sees in store for the broader AI trade.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Apple closing at a record high, as the tech giant continues its recent outperformance over the broader market. But could Apple get left behind as the AI race speeds higher, or can the company keep up with its mega cap peers? Plus, What the Chartmaster Carter Worth sees in the energy sector’s technicals, the comments sending shares of Boeing soaring, and all the after-hours action in names like Crowdstrike, Marvell, and more.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bitcoin feeling the Thanksgiving hangover as the crypto space sells off. The tokens leading the losses, and how the Bitcoin treasury companies are feeling the pain as well. Plus Why the AI tech rally can keep rocking in the new year. Where one top tech analyst sees the most opportunity, as investors digest the latest AI power partnership.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Around the country, a pervasive question being asked: How can I afford my prescription drugs? The high cost of those medications, particularly very expensive drugs to treat serious diseases like multiple sclerosis and cystic fibrosis, have fueled a nationwide business in which insurance programs are using companies called “alternative funding programs” or AFPs that promise to get these medications at little or no cost to the patient. “RiskyRX,” a CNBC investigation, found AFPs are becoming more pervasive around the country as drug costs skyrocket.CNBC submitted nearly 100 public records requests and sorted through more than 10,000 pages of contracts, emails, invoices and complaints that show these companies have penetrated the country’s health-care system through private employers, cities, counties, school districts and unions. In some cases, employers require their staff to use an AFP. CNBC traced the trail of medications from abroad to the U.S. via a supply chain that’s not authorized by the pharmaceutical companies that manufacture the medications. The investigation features an exclusive interview with a Department Of Homeland Security official who says these programs should be shut down because they’re illegal and post a serious safety risk to patients. A former high-ranking FDA official, speaking out for the first time, says these programs typically don’t disclose the risks to patients. The AFPs strongly defend their business practices as both legal and safe and say their businesses are an antidote to high prescription drug prices. Those prices, across all drugs, in the U.S. are nearly three times as much, on average, as those in other high-income countries, according to a 2024 report by Rand, a nonprofit, nonpartisan research organization. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Stocks closing out the week with a big leg higher, as equities rebound after an Nvidia led sell-off on Thursday. The sectors gaining ground, and if the volatility will continue into a shortened holiday week. Plus Rounding up all the retail data and results that came in this week, the huge move in airlines, restaurants, and housing stocks, and where to find opportunity in the credit markets.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

An early rally in stocks gave way to a rough sell-off on Wall Street. How Nvidia’s reversal, and a delayed jobs report gave way to a market meltdown, and how Walmart became a bright spot in the down day. Plus, Biotech more than doubling the performance of the broader market, as M&A action lights up the space. Where our next guest sees the most opportunity in the space, and if the biotech boom can continue into year end.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.